Skip to main content
  • Myocarditis a Risk with Checkpoint Inhibitors

    Occurs early after treatment starts and has malignant course, researchers warn

    Myocarditis following immune checkpoint inhibitor (ICI) therapy may be more common than previously thought, and can occur early in the course of cancer treatment, but it also responds to higher-dose steroids, researchers reported.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details